21.03.2013 • News

DRT Announces Acquisition of SBS from PCAS

DRT, a specialist since 1932 of the valorisation of rosin and turpentine extracted from pine resin, today announced its acquisition of Societe Bearnaise de Synthese (SBS), a company specialized in acrolein-based synthesis intermediates.

Based in Mourenx on the SOBEGI site, SBS produces acrolein derivatives used in fragrances, pharmaceuticals and fine chemicals. SBS employs 12 people at its production plant (6,000 tons capacity on a 10,000 m² site). The company reported net sales of €3.2 million for 2012 and is now the only firm in Europe whose expertise covers the entire acrolein process for these here above applications. SBS today becomes a wholly owned subsidiary of DRT.

DRT's acquisition of SBS guarantees users of acrolein derivatives, in particular for fragrances, not only a choice of supplier but also the certainty working with Mourenx plant that drastic conditions impose by production, handling and transport of these products will be fully respected.

The acquisition also expands DRT's portfolio of ingredients for the fragrance sector and adds a new area of know-how that opens the door to new markets (pharmaceuticals, industry, etc.).

"We saw this acquisition as a real opportunity on two counts," explains Laurent Labatut, Chairman and CEO, DRT. "First of all, by taking over SBS, DRT is saving 12 jobs and keeping a unique body of know-how in France; it also opens up new prospects for the Group to ensure our continued development over the long term," he added.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.